Complete Filing Data
Innate Pharma SA reported Intangible Assets Other Than Goodwill of $0.00 for FY2024.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Innate Pharma SA did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Net Income * | -$49.5M | -$7.6M | -$58.1M | -$52.8M | -$64.0M | -$20.8M | $3.0M | -$48.4M |
| Revenue From Contracts With Customers | $12.6M | $51.9M | $49.6M | $12.1M | $56.2M | $68.6M | $79.9M | $32.6M |
| Research And Development Expense | $52.0M | $56.0M | $51.7M | $47.0M | $49.7M | $62.9M | $69.6M | $67.0M |
| Profit Loss From Operating Activities | -$51.6M | -$12.7M | -$57.4M | -$47.8M | $1.1M | $1.6M | $5.1M | -$40.0M |
| Profit Loss Before Tax | -$49.5M | -$7.6M | -$58.0M | -$45.5M | -$829.0K | $7.9M | $2.7M | -$48.0M |
| Other Comprehensive Income Net Of Tax Gains Losses On Remeasurements Of Defined Benefit Plans | $36.0K | $394.0K | $790.0K | $584.0K | -$200.0K | $622.0K | -$599.0K | $178.0K |
| Other Comprehensive Income Net Of Tax Exchange Differences On Translation | -$504.0K | $276.0K | -$428.0K | -$483.0K | $222.0K | $5.0K | -$26.0K | $68.0K |
| Other Comprehensive Income | -$468.0K | $670.0K | $362.0K | $101.0K | $22.0K | $627.0K | -$625.0K | $683.0K |
| Comprehensive Income | -$49.9M | -$6.9M | -$57.7M | -$52.7M | -$64.0M | -$20.1M | $2.4M | -$47.7M |
| Income Tax Expense Continuing Operations | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$333.0K | $368.0K |
| Other Adjustments To Reconcile Profit Loss | $24.0K | $6.0K | $15.0K | -$1.2M | -$254.0K | $550.0K | $0.00 | |
| Selling General And Administrative Expense | $19.7M | $18.3M | $22.4M | $25.5M | $19.0M | $21.0M | $18.1M | $17.0M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|
| Intangible Assets Other Than Goodwill | $0.00 | $416.0K | $1.6M | $44.2M | $46.3M | $97.0M | $84.5M | $46.2M | $9.1M |
| Cash And Cash Equivalents | $66.4M | $70.6M | $84.2M | $103.8M | $136.8M | $202.9M | $152.3M | $99.4M | $175.9M |
| Noncurrent Financial Assets | $10.3M | $9.8M | $35.1M | $39.9M | $38.9M | $37.0M | $35.2M | $60.5M | |
| Trade And Other Receivables | $14.3M | $66.1M | $52.4M | $48.2M | $51.6M | $28.7M | $139.0M | $21.4M | |
| Trade And Other Payables | $16.0M | $17.0M | $20.9M | $28.6M | $29.5M | $36.0M | $34.7M | $24.6M | |
| Collaboration Liabilities | $48.6M | $52.7M | $63.2M | $40.4M | $46.7M | $21.3M | $31.7M | ||
| Trade And Other Current Receivables | $5.0M | $55.6M | $38.3M | $18.4M | $21.8M | $18.7M | $152.1M | $21.4M | |
| Trade And Other Current Payables | $16.0M | $17.0M | $20.9M | $28.6M | $29.5M | $49.5M | $91.7M | $24.7M | |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | $391.0K | $351.0K | $535.0K | $929.0K | $907.0K | $1.3M | $873.0K | $3.0M | |
| Property Plant And Equipment | $8.5M | $10.2M | $11.7M | $11.7M | $11.3M | $10.7M | $9.1M | ||
| Other Noncurrent Nonfinancial Assets | $575.0K | $87.0K | $149.0K | $148.0K | $147.0K | $89.0K | $86.0K | $111.0K | |
| Noncurrent Liabilities | $69.2M | $83.7M | $103.8M | $80.2M | $106.0M | $62.1M | $87.2M | $95.2M | |
| Noncurrent Financial Liabilities | $22.3M | $31.0M | $40.1M | $13.5M | $16.9M | $16.6M | $3.2M | $4.5M | |
| Noncurrent Assets | $25.3M | $27.2M | $59.5M | $129.2M | $134.0M | $163.8M | $131.6M | $117.5M | |
| Equity And Liabilities | $111.1M | $175.2M | $199.3M | $267.5M | $307.4M | $401.4M | $451.2M | $255.0M | |
| Deferred Income Including Contract Liabilities | $3.4M | $10.5M | $14.5M | $37.9M | $44.0M | $89.1M | |||
| Current Liabilities | $33.0M | $39.6M | $41.3M | $79.9M | $45.5M | $121.8M | $196.7M | $73.9M | |
| Current Financial Liabilities | $8.7M | $8.9M | $2.1M | $30.7M | $2.1M | $2.1M | $1.3M | $1.3M | |
| Current Assets | $85.7M | $148.0M | $139.8M | $138.3M | $173.5M | $237.6M | $319.6M | $137.5M | |
| Cash Flows From Used In Operations Before Changes In Working Capital | -$46.1M | -$467.0K | -$6.7M | -$48.6M | -$2.6M | -$5.3M | $14.6M | -$31.1M | |
| Cash Flows From Used In Operating Activities | -$6.9M | -$32.6M | -$19.2M | -$58.5M | -$51.8M | $34.9M | -$32.5M | -$48.1M | |
| Cash Flows From Used In Investing Activities | $9.2M | $20.6M | $1.9M | -$917.0K | -$13.4M | -$62.1M | $24.3M | -$29.5M | |
| Cash Flows From Used In Financing Activities | -$6.0M | -$2.0M | -$1.8M | $26.8M | -$1.2M | $77.8M | $61.2M | $915.0K | |
| Assets | $111.1M | $175.2M | $199.3M | $267.5M | $307.4M | $401.4M | $451.2M | $255.0M | |
| Adjustments For Increase Decrease In Employee Benefit Liabilities | $324.0K | $285.0K | $365.0K | $437.0K | $216.0K | $685.0K | $477.0K | $381.0K | |
| Noncurrent Receivables | $9.3M | $10.6M | $14.1M | $29.8M | $29.8M | $16.7M | $0.00 | ||
| Purchase Of Other Longterm Assets Classified As Investing Activities | $0.00 | $3.0K | $1.0K | $1.0K | $59.0K | $10.0K | -$25.0K | ||
| Exercise And Subscription Of Equity Instruments | $94.0K | $395.0K | $202.0K | $499.0K | $47.0K | $46.0K | $111.0K | ||
| Current Financial Assets | $14.4M | $21.9M | $17.3M | $16.1M | $14.8M | $16.0M | $15.2M | ||
| Purchase Of Intangible Assets Classified As Investing Activities | $0.00 | $2.0M | $587.0K | $401.0K | $10.4M | $64.1M | $556.0K | $3.1M | |
| Adjustments For Increase Decrease In Trade And Other Payables | -$1.0M | -$3.9M | -$7.7M | -$946.0K | -$6.5M | $1.4M | $1.4M | ||
| Adjustments For Increase Decrease In Collaboration Liabilities | -$4.1M | -$10.5M | $22.8M | -$6.3M | $25.4M | -$10.4M | -$10.4M | ||
| Adjustments For Decrease Increase In Trade And Other Receivables | $51.8M | -$13.7M | -$4.2M | $3.4M | -$22.9M | $110.3M | $110.3M | ||
| Noncurrent Deferred Income Including Noncurrent Contract Liabilities | $2.8M | $4.6M | $7.9M | $25.4M | $32.7M | $40.3M | |||
| Deferred Tax Liabilities | $9.0M | $8.6M | $5.0M | $7.1M | $1.3M | $1.6M | |||
| Deferred Tax Assets | $9.0M | $8.6M | $5.0M | $7.1M | $1.3M | $1.6M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Increase Decrease In Working Capital | -$39.2M | $32.1M | $12.5M | $9.9M | $49.2M | -$40.2M | $47.1M | $17.0M |
| Increase Decrease In Cash And Cash Equivalents | -$4.2M | -$13.6M | -$19.5M | -$33.0M | -$66.1M | $50.6M | $52.9M | -$76.5M |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | -$505.0K | $274.0K | -$428.0K | -$483.0K | $219.0K | $5.0K | -$26.0K | $66.0K |
| Proceeds From Issuing Shares | 2.9M | 395.0K | 198.0K | 499.0K | 48.0K | 44.0K | 111.0K | |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | $0.00 | $150.0K | $0.00 | $7.0K | $9.0K | $0.00 | $0.00 | $50.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Diluted Earnings Loss Per Share | $-0.61 | $-0.09 | $-0.73 | $-0.66 | $-0.81 | $-0.31 | $0.05 | $-0.89 |
| Basic Earnings Loss Per Share | $-0.61 | $-0.09 | $-0.73 | $-0.66 | $-0.81 | $-0.31 | $0.05 | $-0.89 |
| Number Of Shares Issued | 83.8M | 80.9M | 80.2M | 79.6M | 79.0M | 78.8M | 63.9M | 57.6M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Change In Working Capital | $53.7M | $14.1M | $46.2M | $58.7M | $68.5M | $117.7M | $77.5M | |
| Issued Capital | $4.2M | $4.0M | $4.0M | $4.0M | $4.0M | $3.9M | $3.2M | $2.9M |
| Share Premium | $391.0M | $384.3M | $379.6M | $375.2M | $372.1M | $369.6M | $299.9M | $234.9M |
| Repayments Of Borrowings Classified As Financing Activities | $8.9M | $2.4M | $2.0M | $2.1M | $2.2M | $2.0M | $1.3M | $1.2M |
| Other Reserves | $27.0K | $495.0K | $819.0K | $456.0K | $355.0K | -$472.0K | -$1.1M | $180.0K |
| Operating Expense | $71.7M | $74.3M | $115.1M | $72.5M | $68.7M | $83.9M | $87.7M | $84.0M |
| Noncurrent Provisions | $274.0K | $603.0K | $198.0K | $253.0K | $221.0K | $142.0K | $38.0K | $1.0M |
| Increase Decrease Through Sharebased Payment Transactions | $3.9M | $4.3M | $4.2M | $2.6M | $2.5M | $3.8M | $2.7M | $9.8M |
| Finance Income | $6.1M | $6.9M | $4.8M | $6.3M | $4.9M | $11.3M | $6.0M | $2.5M |
| Finance Costs | $4.0M | $1.8M | $5.3M | $4.0M | $6.8M | $5.0M | $8.4M | $10.5M |
| Adjustments For Unrealised Foreign Exchange Losses Gains | -$885.0K | $544.0K | -$912.0K | -$1.1M | $1.3M | -$280.0K | -$1.3M | $3.4M |
| Adjustments For Sharebased Payments | $3.9M | $4.3M | $4.2M | $2.6M | $2.5M | $3.8M | $2.7M | $9.8M |
| Adjustments For Provisions | -$293.0K | -$966.0K | $839.0K | $4.0K | $604.0K | -$484.0K | -$322.0K | $877.0K |
| Adjustments For Fair Value Gains Losses | -$1.3M | -$1.6M | $1.4M | -$987.0K | $577.0K | -$4.1M | $3.8M | -$26.0K |
| Adjustments For Depreciation And Amortisation Expense | $2.0M | $5.1M | $45.4M | $4.6M | $56.8M | $16.5M | $7.4M | $4.4M |
| Current Provisions | $207.0K | $171.0K | $1.5M | $647.0K | $676.0K | $114.0K | $652.0K | |
| Noncurrent Provisions For Employee Benefits | $2.7M | $2.4M | $2.6M | $3.0M | $4.2M | $3.8M | $3.7M | |
| Government Financing For Research Expenditures | $7.5M | $9.7M | $8.0M | $12.6M | $13.6M | $16.8M | $14.1M | |
| Finance Income Cost | $2.1M | $5.1M | -$546.0K | $2.3M | -$1.9M | $6.3M | -$2.4M | -$8.0M |
| Interest Received Classified As Investing Activities | $0.00 | $0.00 | $367.0K | $962.0K | $1.3M | $1.4M | $1.4M | |
| Interest Paid Classified As Financing Activities | $0.00 | $0.00 | $312.0K | $341.0K | $204.0K | $102.0K | $113.0K | |
| Adjustments For Finance Income | $0.00 | $991.0K | $0.00 | $367.0K | $962.0K | $1.3M | $1.4M |
Most recent annual filing with the SEC: April 30, 2025
Data sourced from SEC EDGAR public filings as of August 6, 2026.